Corvus Pharmaceuticals (CRVS) Capital Expenditures (2015 - 2026)
Corvus Pharmaceuticals' (CRVS) quarterly Capital Expenditures came in at $91000.0 in Q1 2026, up 152.78% year-on-year from $36000.0 in Q1 2025, and up 118.69% quarter-over-quarter from -$487000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Capital Expenditures (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Capital Expenditures history runs 12 years deep, the most recent figure standing at $91000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 152.78% year-over-year to $91000.0 in Q1 2026; TTM through Mar 2026 was -$283000.0, a 181.32% decrease from a year earlier, with the FY2025 full-year figure at -$338000.0, down 1307.14% from the prior year.
- Capital Expenditures advanced to $91000.0 in Q1 2026 per CRVS's latest filing, from -$487000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $893000.0 in Q4 2024 and bottomed at -$487000.0 in Q4 2025.
- The 5-year median for Capital Expenditures is $21000.0 (2022), against an average of $6666.7.
- Across the five-year window, Capital Expenditures tumbled 935.29% in 2024 and surged 206.8% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at $257000.0 in 2022, then sank by 86.77% to $34000.0 in 2023, then soared by 2526.47% to $893000.0 in 2024, then tumbled by 154.54% to -$487000.0 in 2025, then soared by 118.69% to $91000.0 in 2026.
- Per Business Quant, the three latest CRVS Capital Expenditures figures stand at $91000.0 (Q1 2026), -$487000.0 (Q4 2025), and $314000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Corvus Pharmaceuticals | 1.23 Bn | 1.23 Bn | - | 91,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Dec 31, 2025 | -487,000.00 |
| Dec 31, 2025 | -487,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Jun 30, 2025 | -201,000.00 |
| Jun 30, 2025 | -201,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Dec 31, 2024 | 893,000.00 |
| Dec 31, 2024 | 893,000.00 |
| Sep 30, 2024 | -294,000.00 |
| Sep 30, 2024 | -294,000.00 |
| Jun 30, 2024 | -287,000.00 |
| Jun 30, 2024 | -287,000.00 |
| Mar 31, 2024 | -284,000.00 |
| Mar 31, 2024 | -284,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Mar 31, 2023 | 34,000.00 |